摘要

Objectives: There are more and more frequent publications about the use of tranexamic acid in rosacea. To date all published studies were on Asian skins. We intend to disclose the results of a clinical trial conducted in Mexico with topical tranexamic acid in patients with rosacea grade1/2. Introduction: Topical tranexamic acid (TTA) is mainly used in the treatment of melasma. Fewer reports exist about its use in erythematotelangiectasic rosacea. Further in this indication only exist reports in Asian skins. For this reason we conducted a clinical trial on Latin American skins in Mexico. The results will be disclosed here for first time. Materials / method: 30 patients (males and females) with bilateral lesions of erythematotelangiectasic rosacea treated in a split-face protocol on one side with 3% TTA cream + photprotector SPF 50 and on the other side with photoprotector SPF 50 alone. 2 daily applications . Duration 1 month. Photos with artificial light taken at D0 and D30. Evaluation at D0 and D30 of erythema, telangiectasia, flushing, itching and burning. Results: Main criterion Percentage of positive responses at D30 vs. placebo, defined by an improvement in at least three of the five evaluated characteristics (erythema, telangiectasias, flushing, itching and burning) = 56.7% vs. 20.0% (p<0.0001) Evolution of erythema 49.0% vs. 13.2% (p<0.001) Evolution of telangiectasias 57.8% vs. 22.1% (p<0.05) Evolution of flushing 55.5% vs. 39.6% (p<0.01) Evolution of itching 90.9% vs. 20.0% (p<0.01) Evolution of burning 86.4% vs. 22.0% (p<0.01) 96.7% of patients showed a good tolerance to the treatment and no side effect was reported. Conclusion: Topical tranexamic acid constitutes an efficient and safe alternative in the treatment of erythematotelangiectasic rosacea.